Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma
James Godfrey, Lei Gao, Geoffrey Shouse, Joo Y. Song, Stacy Pak, Brian Lee, Bihong T. Chen, Avyakta Kallam, John H. Baird, Guido Marcucci, Lucy Ghoda, Stéphanie Vauléon, Alexey V. Danilov, Alex F. Herrera, Larry W. Kwak, Lihua E. Budde
Abstract
ABSTRACT: Although CD20×CD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in central nervous system (CNS) lymphoma is unknown. Here, we report the CD20×CD3 bispecific glofitamab penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces clinical responses in patients with secondary CNS.
Topics & Concepts
LymphomaImmune systemInfiltration (HVAC)Blood–brain barrierMedicineCentral nervous systemAntibodyPathologyCancer researchImmunologyBiologyInternal medicinePhysicsThermodynamicsCNS Lymphoma Diagnosis and TreatmentLymphoma Diagnosis and TreatmentCAR-T cell therapy research